Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent must be obtained before any study assessment is performed.
Males and females of non-childbearing potential ≥ 18 years of age.
Subjects with mild to moderate essential hypertension,
* Untreated subjects must have a mean seated SBP (msSBP) ≥ 130 mmHg and \< 180 mmHg at screening.
* Pre-treated subjects must have a msSBP ≤ 160 mmHg at screening and \< 180 mmHg at the end of the washout period.
Waist circumference ≥ 102 cm (men) and ≥ 88 cm (women);
You may not be if
Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer; or longer if required by local regulations.
History of angioedema, drug-related or otherwise
History of hypersensitivity to LCZ696, amlodipine, or drugs of similar chemical classes.
Severe hypertension (grade 3 of WHO classification; msDBP ≥100 mmHg and/or msSBP ≥ 180 mmHg) at screening or at the end of the washout period.
Type 1 or Type 2 diabetes mellitus.
Dyslipidemia requiring pharmacological therapy with a fibrate or nicotinic acid.
Concomitant use of anti-hypertensives, anti-diabetics, or drugs with effects on glucose or lipid metabolism for the duration of the study.
Clareo Health | Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects
